18 assets in Endometrioid Adenocarcinoma

Therapeutic assets addressing Endometrioid Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Avutometinib Endometrioid Adenocarcinoma	University of Oklahoma	P2	B (60)
Carboplatin Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	B (60)
Defactinib Endometrioid Adenocarcinoma	University of Oklahoma	P2	B (60)
Indocyanine Green Endometrioid Adenocarcinoma	Centre Oscar Lambret	P3	B (60)
Patent Blue Violet Endometrioid Adenocarcinoma	Centre Oscar Lambret	P3	B (60)
Cediranib Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	B (57)
Capivasertib Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Dostarlimab Endometrioid Adenocarcinoma	University Health Network, Toronto	P2	CCC (53)
Durvalumab Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Niraparib Endometrioid Adenocarcinoma	University Health Network, Toronto	P2	CCC (53)
Nivolumab Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Olaparib Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Pasifolate Exatecan Endometrioid Adenocarcinoma	Elucida Oncology	P1/2	CCC (48)
Medroxyprogesterone Endometrioid Adenocarcinoma	Peking University People's Hospital	N/A	D (30)
Megestrol Acetate Endometrioid Adenocarcinoma	Peking University People's Hospital	N/A	D (30)
Pembrolizumab Endometrioid Adenocarcinoma	Peking University People's Hospital	N/A	D (30)
Adriamycin Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2	NR ()